FDA accepts BMS' sBLA for Opdivo-Yervoy combo for HCC

By Yahoo! Finance | Aug 22, 2024 at 04:45 AM EST

The FDA accepted BMS's sBLA for Opdivo and Yervoy as a potential first-line treatment for unresectable hepatocellular carcinoma. The submission is based on positive results from the Phase III CheckMate -9DW trial, showing significant overall survival improvement.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.